A promising enzymatic-based point-of-care assay for a rapid and accurate quantification of three new factor XI(a) inhibitors: asundexian, milvexian and abelacimab

milvexian (BMS-986177) - BMS, J&J

abelacimab (MAA868) - Anthos Therapeutics

asundexian (BAY 2433334) - Bayer

Sophie LE BELLEGO 1; Antoine LEROY 1; Sandra SANFILIPPO 1; Leslie BUISSON 1; Thibault DONNET 1

May 25, 2026